Background: Seroconversion and longevity of vaccine-induced immune response is blunted
in immune-mediated inflammatory disease (IMID) patients owing to immunosuppressive …

Background Patients with autoimmune rheumatic diseases (ARD) are at a potentially higher
risk for COVID-19 infection complications. Given their inherent altered immune system and …

Objective Patients with immune‐mediated inflammatory diseases (IMIDs) receiving B cell–
depleting therapy (BCDT) are among the most vulnerable to severe COVID‐19, as well as …

Objectives Patients under rituximab therapy are at high risk for a severe COVID-19 disease
course. Humoral immune responses to SARS-CoV-2 vaccination are vastly diminished in B …

With the emergence of SARS-CoV-2 variants, vaccine breakthrough is a major public health
concern. With evidence of reduced neutralizing antibody activity against Omicron variants …

Background Patients with autoimmune/inflammatory conditions on anti-CD20 therapies,
such as rituximab, have suboptimal humoral responses to vaccination and are vulnerable to …

Vasculitides, a form of inflammatory autoimmune disease targeting the vessels, constitute an
entity with significant morbidity and mortality. Infections have long been associated with …

Objective To assess factors associated with serologic response to the coronavirus 2019
(COVID-19) booster vaccine in patients with autoimmune rheumatic diseases treated with …

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has represented a major challenge to …

Emerging omicron subtypes with immune escape lead to inadequate vaccine response with
breakthrough infections in immunocompromised individuals such as Anti-neutrophil …